This capstone answers the question the rest of the cluster builds toward: what does the microdosing evidence actually cover? In substance terms, almost only psilocybin and LSD. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 The surveys, the field overviews, and the handful of controlled studies are dominated by these two, with psilocybin most represented; [2] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 everything else has little or no controlled low-dose human evidence. And even for the leading pair the data are thin and largely uncontrolled, with blinded work suggesting much reported benefit is expectation. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 The cluster’s anchor, restated: knowing what a substance is — its class, target, and full-dose pharmacology — is not knowing it works at a microdose; for almost everything except psilocybin and LSD, the compound is described far better than its microdosing evidence.
This is an education-only research summary, not sourcing, dosing, medical, or legal advice. It describes the shape and limits of the microdosing evidence base by substance. It makes no claim that any substance is effective or safe at a microdose and recommends none. For personal decisions, consult a qualified clinician.
The evidence is narrow in substance coverage
It is natural to talk about “microdosing” as if it were one well-defined thing studied across many substances. It is not. A systematic review of low-dose psychedelic research covering more than six decades found the literature concentrated overwhelmingly in psilocybin and LSD, and otherwise sparse. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 A field overview characterised microdosing as having more open questions than settled answers, with even basic repeated-low-dose pharmacology unmapped. [2] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 So a general statement about “microdosing benefits” is, in practice, a statement about two substances — and a weak one at that.
| Substance | Controlled low-dose human evidence |
|---|---|
| Psilocybin | Most — surveys and a few small studies |
| LSD | Some — including self-blinding work |
| DMT / mescaline | Essentially none |
| Ketamine / MDMA | Not microdosing (full/clinical dosing only) |
| Novel chemicals | None |
Coverage is not endorsement
The fact that psilocybin and LSD are better represented in microdosing research does not mean either is recommended, proven effective, or broadly safe. It means the evidence base is less empty there than for other substances. Greater coverage is a statement about where studies have been done, not a verdict about what works or what anyone should take. The matrix below reads as a map of where evidence exists and what limits it — not a ranking.
| Substance / category | Direct microdosing research | Main interpretation limit |
|---|---|---|
| Psilocybin | Relatively more represented | Expectation, mushroom variability, limited controlled evidence |
| LSD | Some direct controlled / self-blinding research | Long duration, expectation, dose precision outside labs |
| Mescaline | Sparse | Little direct microdosing evidence |
| DMT / ayahuasca | Sparse as microdosing | Route, preparation, and context differences |
| Ketamine / MDMA / ibogaine | Not transferable from classic psychedelic evidence | Different pharmacology and safety concerns |
| Research chemicals | Weakest | Identity, purity, safety, and evidence gaps |
…and weak in design where it exists
Even concentrated in psilocybin and LSD, the evidence is mostly observational. Large survey cohorts report that people who microdose describe health motivations and lower anxiety and depression than non-microdosers — but these are self-selected groups who expect benefit, and such designs cannot separate a drug effect from expectation. [4] Observational Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers doi:10.1038/s41598-021-01811-4 An early influential exploration was itself an open survey of enthusiasts. [5] Observational Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration doi:10.1080/02791072.2019.1593561 The most informative design to date, a self-blinding citizen-science study, found improvements in microdosers that also appeared in the placebo group, with the gap between them largely explained by expectancy. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 Being the best-studied substances in a methodologically weak field makes psilocybin and LSD the least poorly studied, not well established.
| What looks reassuring | What it actually is |
|---|---|
| Many publications on microdosing | Mostly surveys of self-selected enthusiasts |
| Reported mood and anxiety benefits | Uncontrolled self-report, expectation-laden |
| A landmark blinded study exists | It found placebo matched much of the benefit |
| Two substances well represented | A narrow base in a weak field |
Description is not demonstration
The cluster’s recurring lesson lands hardest here. Across these pages, each substance can be described — its chemical family, its 5-HT2A or other target, its full-dose pharmacology — sometimes in considerable detail. [2] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 None of that description amounts to a demonstration that a microdose of the substance produces a benefit. A well-characterised compound with no low-dose evidence is exactly that: well-characterised and unproven at a microdose. Confusing the two — reading a pharmacology fact as an efficacy claim — is the central error this cluster is built to prevent. The corrective rule is compound-specific: a microdosing claim should be tied to the compound and dose context actually studied — evidence from psilocybin does not automatically apply to LSD, evidence from LSD does not extend to mescaline or DMT or research chemicals, and full-dose findings do not transfer to sub-perceptual repeated dosing. For how the field studies low doses and why it is hard, see microdosing in the research literature and why microdosing is difficult to study; for what the evidence can and cannot certify on safety, the limits-of-safety-claims capstone.
- Two substances, really
- The microdosing evidence base is essentially psilocybin and LSD. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
- Quantity ≠ quality
- Most of even that literature is uncontrolled self-report. [4] Observational Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers doi:10.1038/s41598-021-01811-4
- Blinding changes the story
- The self-blinding study showed placebo matched much of the reported benefit. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878
- Described ≠ demonstrated
- A well-characterised compound can have no microdosing evidence at all.
Frequently asked questions
Which substances does the microdosing evidence actually cover?
Almost entirely two: psilocybin and LSD. The systematic reviews, the surveys, and the small number of controlled studies are dominated by these, with psilocybin the most represented. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 For every other substance — DMT, mescaline, ketamine, MDMA, novel analogues — there is little or no controlled low-dose human evidence; what exists is full-dose, mechanistic, or anecdotal. So a general claim about “microdosing” is, in practice, a claim about psilocybin and LSD, and even there the evidence is thin and largely uncontrolled.
If the evidence is mostly psilocybin and LSD, why is it still called thin?
Because quantity is not quality. The bulk of the literature is observational surveys and self-report from people who already microdose and expect benefit, which cannot separate a drug effect from expectation. [4] Observational Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers doi:10.1038/s41598-021-01811-4 The few blinded studies, including a self-blinding citizen-science design, found that much of the reported benefit appeared on placebo too. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 Being the best-studied substances in a field that is itself methodologically weak does not make psilocybin and LSD well established at microdose level — it makes them the least poorly studied.
Does describing a substance well mean its microdosing is supported?
No, and this is the capstone’s whole point. A compound can have a thoroughly characterised chemical class, receptor target, and full-dose pharmacology and still have essentially no evidence that a microdose of it does anything. [2] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 Description and demonstration are different achievements. For most substances in this cluster the compound is described far better than any microdosing effect, and confusing the two is how a pharmacology fact gets mistaken for an efficacy claim.
What would change this picture?
Larger, properly blinded, placebo-controlled trials with verified doses and pre-registered outcomes, across defined populations and longer follow-up — and, for substances beyond psilocybin and LSD, essentially any controlled low-dose human research at all. [5] Observational Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration doi:10.1080/02791072.2019.1593561 Until then, the accurate summary is that the microdosing evidence base is narrow in substance coverage and weak in design. This cluster reflects that by describing what each compound is and routing efficacy and safety questions to where the evidence, and its limits, are discussed directly.